The need for high throughput kinetics early in the drug discovery process

Drug Discovery World

Volumn 12, Issue 3, 2011, Pages 39-45

  Keighley, Wilma ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATROPIUM; CLIDINIUM; ICI 137798; IPRATROPIUM BROMIDE; MUSCARINIC M3 RECEPTOR ANTAGONIST; NEUROPEPTIDE Y; PEPTIDE YY; SCH 527123; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

DRUG MANUFACTURE; DRUG RESEARCH; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; REVIEW; TECHNOLOGY;

EID: 79961007102     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Andersson, K et al (2006). Expert Opin. Drug Disc., 1, 439-446.
2. Copeland, RA et al (2006). Nature Rev.Drug Disc., 5, 730-739.
3. Zhang, R and Monsma, F (2009). Curr. Opin. Drug Disc. Dev., 12, 488-496
4. Lindström, E et al (2007). JPET., 322, 1286-1293.
5. Rigby, J W et al (1988). J. Cardiovasc. Pharmacol., 12, Suppll.6, S144.
6. Napier, C et al (2005). Biochem. Pharmacol., 31, 163-72.
7. Gradman, AH (2002). J. Human Hypertension 16, S9-S16.
8. Markgren, P-O et al (2002). J. Med. Chem., 45, 5430-5439.
9. Disse, B et al (1999) Life Sci., 64, 457-464.
10. Noorda, JA van et al (2000). Thorax 55, 289-294.
11. Elg, M et al (1997). Thromb. Haemost., 78, 1286-1292.
12. Geitmann, M et al (2006). J. Med. Chem., 49, 2367-2374.
13. Comley, J. (2008). Drug Discovery World Fall edition, 28-49.
14. Boettcher, ,A et al (2010). J Biomol. Screen. 15, 1029-41.
15. Rich, L and Myszka, DG (2010). J. Mol. Recognit. 23, 1-64.
16. Rich, RL et al (2010). Anal. Biochem., 407, 270-277.
17. Navratilova, I et al (2011). ACS Med. Chem. Lett., Article ASAP DOI: 10.1021/m/2000017.
18. Dautzenberg, FM and Naysari, S (2005). Pharmacol., 75, 21-29.
19. Keith, RA et al (1989). JPET., 248, 240-248.
20. Gonsiorek, W et al (2007). JPET., 322, 477-485.
21. Abbas, A et al (2011). Biosens. Bioelectron., 26, 1815-1824.
22. Navratilova, I and Hopkins AL (2010). ACS Med. Chem. Letts 1, 44-48.